Targeted therapies such as KRAS G12C inhibitors, along with immune checkpoint inhibitors targeting PD-L1, have significantly advanced the treatment landscape for KRAS-mutant NSCLC [9]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.